Global Sickle-cell Anemia Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Sickle-cell Anemia Therapeutics Market Growth (Status and Outlook) 2023-2029

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

LPI (LP Information)' newest research report, the “Sickle-cell Anemia Therapeutics Industry Forecast” looks at past sales and reviews total world Sickle-cell Anemia Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Sickle-cell Anemia Therapeutics sales for 2023 through 2029. With Sickle-cell Anemia Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sickle-cell Anemia Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Sickle-cell Anemia Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sickle-cell Anemia Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sickle-cell Anemia Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sickle-cell Anemia Therapeutics and breaks down the forecast by type, by user, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sickle-cell Anemia Therapeutics.

The global Sickle-cell Anemia Therapeutics market size is projected to grow from US$ 1805.8 million in 2022 to US$ 4969.7 million in 2029; it is expected to grow at a CAGR of 15.6% from 2023 to 2029.

In the last several years, global market of Sickle Cell Anemia Therapeutics developed rapidly, with an average growth rate of 13.32% during 2013 to 2017. In 2017, global revenue of Sickle Cell Anemia Therapeutics is nearly 1900 M USD.

This report presents a comprehensive overview, market shares, and growth opportunities of Sickle-cell Anemia Therapeutics market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant

Segmentation by user
Child
Adult

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.